NCT01993368

Brief Summary

Periodontitis are inflammatory diseases characterized by the destruction of the tooth-supporting bone due to increased bone resorption by osteoclasts (OCLs). Two forms are described: chronic periodontitis (CP) and aggressive periodontitis (AP) that differ by the severity and rapidity of bone loss, much more important for AP than CP. In both forms, the link with uncontrolled activation of the immune system is largely admitted. Despite the physiopathology of CP is fairly well studied, very few data are available regarding AP. The investigators aim is to understand the severity of AP by analyzing the proportion and action of immune and mesnchymal cells potentially involved in bone destruction, on biopsies of periodontal granulation tissue (surgical waste) and blood. Three groups of 20 patients will be included: affected with AP, CP or controls (necessitating an extraction of wisdom teeth).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2013

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

November 15, 2013

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 25, 2013

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

February 7, 2018

Status Verified

February 1, 2018

Enrollment Period

4.1 years

First QC Date

November 15, 2013

Last Update Submit

February 6, 2018

Conditions

Keywords

wisdom teeth extraction

Outcome Measures

Primary Outcomes (1)

  • proportion of lymphocytes, myeloid and mesenchymal populations in the samples

    determined by flow cytometry

    At the surgery time

Study Arms (3)

chronic periodontitis

OTHER

biopsy of periodontal granulation tissue (surgical waste)

Other: flow cytometry

aggressive periodontitis (AP)

OTHER

biopsy of periodontal granulation tissue (surgical waste)

Other: flow cytometry

controls

OTHER

necessitating an extraction of wisdom teeth

Other: flow cytometry

Interventions

These populations will be identified by different combinations of antibodies to identify: * T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56). * Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR) * Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)

Also known as: proportion of lymphocytes, myeloid and mesenchymal populations in the samples, as determined by flow cytometry.
aggressive periodontitis (AP)chronic periodontitiscontrols

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Young patients not suffering of any médical conditions
  • Small amount of calculus detected
  • Pocket depth \>5mm
  • Alveolar Bone loss \>50%
  • Evident presence of calculus above or under the gingiva
  • Pocket depth \>5mm
  • Young patients in need of impacted wisdom teeth removal
  • And not suffering of chronic or agressive periodontitis

You may not qualify if:

  • Patients with blood disorder
  • Patients presenting with liver, kidney, or vascular disorder, and /or psychiatric disorder
  • Patients who have allergies
  • Patients taking biphosphonates, anticoagulant drugs, or anticonvulsivant
  • Patients who have had a cancer of the mouth, and/or treated by radiotherapy
  • Patients who have taken anti-inflammatory drugs, and/or anti-cancer drugs, and/or immuno-suppresive drugs in the past 6 months
  • Patients who have had a periodontal treatment in the past 12 months
  • Pregnant Women
  • Patients juged difficult to follow by the investigator
  • Vulnerable patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Odontology Department, Nice Unversity Hospital

Nice, 06000, France

Location

MeSH Terms

Conditions

Aggressive PeriodontitisChronic Periodontitis

Interventions

Flow Cytometry

Condition Hierarchy (Ancestors)

PeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Cell SeparationCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisCytophotometryFluorometryLuminescent MeasurementsPhotometryChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Jérôme SURMENIAN, MD

    Odontology Department, NIce University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 15, 2013

First Posted

November 25, 2013

Study Start

November 1, 2013

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

February 7, 2018

Record last verified: 2018-02

Locations